SG11201507286QA - Methods and systems for conditioning of particulate crystalline materials - Google Patents

Methods and systems for conditioning of particulate crystalline materials

Info

Publication number
SG11201507286QA
SG11201507286QA SG11201507286QA SG11201507286QA SG11201507286QA SG 11201507286Q A SG11201507286Q A SG 11201507286QA SG 11201507286Q A SG11201507286Q A SG 11201507286QA SG 11201507286Q A SG11201507286Q A SG 11201507286QA SG 11201507286Q A SG11201507286Q A SG 11201507286QA
Authority
SG
Singapore
Prior art keywords
conditioning
systems
methods
crystalline materials
particulate crystalline
Prior art date
Application number
SG11201507286QA
Inventor
Ali Kazmi
David Lechuga
Herm Snyder
James Ivey
Reinhard Vehring
Jason H Speck
Sarvajna Dwivedi
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50487199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201507286Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of SG11201507286QA publication Critical patent/SG11201507286QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C19/00—Other disintegrating devices or methods
    • B02C19/06—Jet mills
SG11201507286QA 2013-03-15 2014-03-14 Methods and systems for conditioning of particulate crystalline materials SG11201507286QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799956P 2013-03-15 2013-03-15
PCT/US2014/029489 WO2014144894A1 (en) 2013-03-15 2014-03-14 Methods and systems for conditioning of particulate crystalline materials

Publications (1)

Publication Number Publication Date
SG11201507286QA true SG11201507286QA (en) 2015-10-29

Family

ID=50487199

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507286QA SG11201507286QA (en) 2013-03-15 2014-03-14 Methods and systems for conditioning of particulate crystalline materials

Country Status (18)

Country Link
US (3) US20140275517A1 (en)
EP (1) EP2968152B2 (en)
JP (1) JP6454323B2 (en)
KR (2) KR102391332B1 (en)
CN (1) CN105188679B (en)
AU (1) AU2014228414B2 (en)
BR (1) BR112015022784B1 (en)
CA (1) CA2905542C (en)
ES (1) ES2712988T5 (en)
HK (2) HK1219223A1 (en)
IL (1) IL240759B (en)
MX (1) MX361286B (en)
MY (1) MY178819A (en)
RU (1) RU2696582C2 (en)
SG (1) SG11201507286QA (en)
TR (1) TR201902687T4 (en)
WO (1) WO2014144894A1 (en)
ZA (1) ZA201506176B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
PL3346990T3 (en) 2015-09-09 2020-08-24 Vectura Limited Jet milling method
EP3490533B1 (en) 2016-07-29 2020-05-27 Inke, S.A. Particle size stabilization process
IT201600098452A1 (en) * 2016-09-30 2018-03-30 Micro Macinazione Sa EQUIPMENT FOR THE MICRONIZATION OF DUSTY MATERIAL WITH THE ABILITY TO PREVENT SCREENING

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3175299A (en) * 1961-08-02 1965-03-30 American Sugar Method of drying sugar crystals with acoustic energy and a gas
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (en) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Pharmaceutical compositions comprising salmeterol and fluticasone propionate
NZ235222A (en) 1989-09-08 1992-11-25 Glaxo Group Ltd Inhalatory composition comprising salmeterol and beclomethasone dipropionate
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
JPH0725789B2 (en) 1990-09-10 1995-03-22 シェリング・コーポレーション Mometasone furoate-hydrate, process for its production and pharmaceutical composition
DE4108393A1 (en) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg NEW ESTERS BI-AND TRICYCLIC AMINO ALCOHOLS, THEIR PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (en) 1991-04-11 1991-04-11 Astra Ab PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
DK0613371T3 (en) 1991-12-18 2002-05-13 Astrazeneca Ab New combination of formoterol and budesonide
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
ATE233544T1 (en) 1993-12-02 2003-03-15 Abbott Lab AEROSOLS AS A DOSAGE FORM WITH CFC-FREE PROPELLANT
SE9404080L (en) 1993-12-28 1995-06-29 Ciba Geigy Ag Process for preparing an optically pure enantiomer of formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
WO1995022036A1 (en) 1994-02-09 1995-08-17 Kinerton Limited Process for drying a material from solution
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (en) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
EE9700138A (en) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosol formulations
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6136346A (en) 1995-04-14 2000-10-24 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (en) 1996-04-12 1999-12-16 Biovision Gmbh Process for the production of a biodegradable bone replacement and implant material and biodegradable bone replacement and implant material
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
SE9700135D0 (en) 1997-01-20 1997-01-20 Astra Ab New formulation
SK284919B6 (en) 1997-03-20 2006-02-02 Schering Corporation Method of producing powder agglomerates and dosage form comprising thereof
US6129905A (en) 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (en) 1997-09-19 1997-09-19 Astra Ab New use
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
AU750567B2 (en) 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9808470D0 (en) † 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
US6260549B1 (en) 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DK1102579T3 (en) 1998-08-04 2003-07-14 Jago Res Ag Medical aerosol formulations
HU226164B1 (en) 1998-11-13 2008-05-28 Jagotec Ag Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation
GB9912639D0 (en) 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) † 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
AU771984B2 (en) 1998-12-22 2004-04-08 University Of North Carolina At Chapel Hill, The Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
BR9917246A (en) 1999-03-05 2002-03-26 Chiesi Farma Spa Advanced pharmaceutical compositions for inhalation powder
SE9900833D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (en) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
ATE233084T1 (en) 1999-04-14 2003-03-15 Glaxo Group Ltd PHARMACEUTICAL AEROSOL FORMULATION
US20100197719A1 (en) 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
JP4130078B2 (en) * 1999-06-03 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Carbapenem derivative crystals and injection preparations
WO2001000312A1 (en) † 1999-06-30 2001-01-04 Inhale Therapeutic Systems, Inc. Spray drying process for preparing dry powders
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
PT102343B (en) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa METHOD FOR THE PREPARATION OF FUROATE MOMETHASONE
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
CA2389219C (en) 1999-10-29 2009-06-23 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20040081627A1 (en) 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
EP2283818B1 (en) 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
ITMI20010428A1 (en) 2001-03-02 2002-09-02 Chemo Breath S A INHALATION COMPOSITIONS BASED ON FORMOTEROL
BR0208012A (en) 2001-03-20 2004-03-02 Glaxo Group Ltd Uses of at least two drugs and one hfa propellant and at least one pharmaceutical composition and inhaler packaged to treat asthma
CN100496608C (en) 2001-03-30 2009-06-10 洁垢技术有限公司 Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10120484A1 (en) * 2001-04-25 2002-10-31 Degussa Method and device for the thermal treatment of powdery substances
DE10130371A1 (en) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI324934B (en) 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
DE10202940A1 (en) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Cartridge for a powder inhaler
AU2003230611A1 (en) 2002-03-07 2003-09-22 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
DE10214264A1 (en) 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA suspension formulations of an anhydrate
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (en) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Synergistic medicaments for treating inflammatory or obstructive respiratory tract diseases, containing quaternized scopine ester anticholinergic agent and steroid, e.g. budesonide
KR20060011783A (en) 2002-06-12 2006-02-03 에피제네시스 파마슈티칼스 아이엔씨 Composition, formulations and kit for treatment of respiratory and lung disease with dehydroepi androsterone(s) steroid and an anti-muscarinic agent(s)
DE10237739A1 (en) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalable medicament for treating inflammatory or obstructive respiratory diseases, containing synergistic combination of tropane derivative anticholinergic agent, corticosteroid and beta-mimetic agent
US7244742B2 (en) 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
US6942821B2 (en) 2002-10-15 2005-09-13 Cryovac, Inc. Process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
DE10323966A1 (en) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting drug combinations for the treatment of respiratory diseases
KR20060015316A (en) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
US7238664B2 (en) 2003-06-16 2007-07-03 Altana Pharma Ag Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases
SE527190C2 (en) 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
EP1651221B1 (en) 2003-07-28 2009-01-14 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic agent
RU2375059C2 (en) 2003-07-29 2009-12-10 Бёрингер Ингельхайм Интернациональ Гмбх Inhalation medicines containing beta-memetics and anticholinergic agent
BRPI0413054A (en) 2003-07-29 2006-10-17 Boehringer Ingelheim Int combination of an anticholinergic and a steroid and its use in the treatment of inhalation breathing disorders
EP1651224B1 (en) 2003-07-31 2011-10-05 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising an anticholinergic and a betamimetic
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
SE0303270L (en) 2003-12-03 2005-06-04 Microdrug Ag Method of administration of tiotropium
EP1713473B1 (en) 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
PL1718336T3 (en) 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
WO2005077339A1 (en) 2004-02-10 2005-08-25 E.I. Dupont De Nemours And Company Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2005115520A1 (en) * 2004-05-20 2005-12-08 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
DK1765288T3 (en) 2004-06-18 2013-02-11 Novartis Ag Tobramycin preparations for the treatment of endobronchial infections
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US7915303B2 (en) 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
JP2008534611A (en) 2005-03-30 2008-08-28 シェーリング コーポレイション Drugs and methods combining anticholinergics, corticosteroids and long acting beta agonists
JP2008538758A (en) 2005-04-23 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for inhalation containing beta-receptor stimulant and steroid in addition to anticholinergic
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
WO2006128847A2 (en) 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Method of particle formation
CN100560598C (en) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 The synthetic method of FLUTICASONE PROPIONATE
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
DE602006008665D1 (en) 2005-12-21 2009-10-01 Meda Pharma Gmbh & Co Kg COMBINATION OF R, R-GLYCOPYRROLATE, ROLIPRAM AND BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
WO2007095041A2 (en) 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
CA2653105A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2008217586A1 (en) 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (en) 2008-12-22 2011-02-25 Boehm & Cie Ets MULTI-PURPOSE TOOL WITH MECHANISM ABSORBING ENERGY TRANSMITTED BY MEANS OF GRIPPING
WO2010097188A1 (en) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
SI2435024T1 (en) 2009-05-29 2016-10-28 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20150093440A1 (en) † 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
US20140308214A1 (en) 2011-02-17 2014-10-16 Cipla Limited Pharmaceutical Composition
JO3510B1 (en) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd Use of glycopyrrolate for treating tachycardia
SG194896A1 (en) 2011-05-17 2013-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
US20120325942A1 (en) 2011-06-27 2012-12-27 General Electric Company Jet milling of boron powder using inert gases to meet purity requirements
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials

Also Published As

Publication number Publication date
EP2968152B1 (en) 2018-11-28
KR102391332B1 (en) 2022-04-26
KR102275109B1 (en) 2021-07-07
JP6454323B2 (en) 2019-01-16
US11471468B2 (en) 2022-10-18
EP2968152B2 (en) 2022-06-22
RU2696582C2 (en) 2019-08-05
TR201902687T4 (en) 2019-03-21
ES2712988T3 (en) 2019-05-17
HK1219223A1 (en) 2017-03-31
IL240759B (en) 2019-11-28
MX361286B (en) 2018-12-03
EP2968152A1 (en) 2016-01-20
MX2015013217A (en) 2015-12-11
MY178819A (en) 2020-10-20
WO2014144894A1 (en) 2014-09-18
RU2015144286A3 (en) 2018-03-23
ZA201506176B (en) 2019-04-24
CA2905542A1 (en) 2014-09-18
AU2014228414B2 (en) 2018-09-13
IL240759A0 (en) 2015-10-29
CA2905542C (en) 2022-05-03
AU2014228414A1 (en) 2015-09-10
NZ711200A (en) 2020-09-25
KR20210032555A (en) 2021-03-24
BR112015022784A2 (en) 2017-07-18
CN105188679A (en) 2015-12-23
BR112015022784B1 (en) 2023-02-14
US20200368251A1 (en) 2020-11-26
ES2712988T5 (en) 2022-10-21
US20140275517A1 (en) 2014-09-18
RU2015144286A (en) 2017-04-24
CN105188679B (en) 2018-10-16
US20180344747A1 (en) 2018-12-06
JP2016515931A (en) 2016-06-02
KR20160005685A (en) 2016-01-15
HK1219059A1 (en) 2017-03-24

Similar Documents

Publication Publication Date Title
HK1217539A1 (en) Systems and methods for detection of cells using engineered transduction particles
HK1225842A1 (en) Methods and systems for managing shipped objects
IL246087A0 (en) Materials and methods for controlling infections
ZA201504903B (en) Systems and methods for access-controlled interactions
HK1218429A1 (en) Non-replicative transduction particles and transduction particle- based reporter systems
EP3071330A4 (en) Microfluidic methods and systems for isolating particle clusters
EP2962265A4 (en) Systems and methods for improved maintenance of patient-associated problem lists
EP2989616A4 (en) Methods, devices, and systems for secure transport of materials
EP2938459A4 (en) Particulate materials and methods of forming same
ZA201504490B (en) Systems and methods for sample handling
EP2968044A4 (en) Bed systems and methods
EP2951684A4 (en) Systems and methods for managing navigation among applications
EP2976744A4 (en) Systems and methods for managing sending of items
HUE048132T2 (en) Aircraft and particulate detection method
PL3470129T3 (en) Air filter system and air filter element for an air filter system
ZA201506133B (en) Air filter systems and methods of using the same
HK1214183A1 (en) Methods and materials for detection of biologicals
PL3011244T3 (en) Feed flow conditioner for particulate feed materials
GB2518485B (en) Systems and methods for locating and prioritizing cargo
HK1219059A1 (en) Methods and systems for conditioning of particulate crystalline materials
EP3020020A4 (en) Systems and methods for knowledge management
EP2973393A4 (en) Methods and systems for structural analysis
EP3028169A4 (en) Systems and methods for measurement equivalency
EP2967491A4 (en) Methods and systems for characterizing an object
GB201415815D0 (en) Size reduction device and method for the size reduction of solid particles